<DOC>
	<DOC>NCT02953860</DOC>
	<brief_summary>A phase 2 study to evaluate the tolerability and clinical activity of adding enzalutamide to fulvestrant treatment in women with advanced breast cancer that are ER and/or PR positive and Her2 normal.</brief_summary>
	<brief_title>Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer</brief_title>
	<detailed_description>This is a single arm, non-randomized, open-label phase 2 study designed to evaluate the tolerability and clinical activity of adding enzalutamide to fulvestrant treatment in women with advanced breast cancer that are ER and/or PR-positive and Her2 normal. In this study 500 mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be, in conjunction with Fulvestrant, PO daily.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>ER+ Her2 breast cancer Metastatic At least 18 years of age Candidate for fulvestrant therapy patients who have started fulvestrant may enter this trial if within 3 months of starting fulvestrant Measurable or Evaluable by RECIST 1.1 PS 02 Able to swallow study drug and comply with study requirements Tumor available for fresh biopsy (two biopsies pretreatment as regards enzalutamide, and during treatment @4 weeks). (The patient will be asked if they would be willing to provide a third biopsy at time of progression) Patients may already have gotten the loading doses of fulvestrant and/or ovarian suppression If patient is pre or peri menopausal, then will need to have concurrent ovarian suppression. ANC &gt;1000/uL, platelets &gt;75,000/uL at screening visit Total bilirubin &lt; 1.5 times upper limit of normal (ULN) at the screening visit unless an alternate nonmalignant etiology exists (eg, Gilbert's disease) Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &lt; 3 times ULN or &lt; 5 times ULN if patient has documented liver metastases Creatinine &lt; 1.5 times ULN INR &lt; 1.5 times ULN, or if on warfarin, can safely transition off for biopsy Willing to donate blood for research at 4 time points Written informed consent obtained prior to biopsies and blood samples Current or previously treated brain or leptomeningeal metastases History of seizures Prior treatment with an antiandrogen (abiraterone, ARN509, bicalutamide, enzalutamide, ODM201, TAK448, TAK683, TAK700, VT464). Systemic estrogens or androgens within 14 days before initiating therapy. Vaginal estrogens are allowed if necessary for patient comfort.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>101 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced Breast Cancer</keyword>
	<keyword>ER+/Her2 Advanced Breast Cancer</keyword>
</DOC>